Center for Stem Cell Biology and Engineering, Neuroscience Research Institute, Department of Molecular, Cellular and Developmental Biology, University of California, Santa Barbara, California, USA.
Stem Cells. 2015 Aug;33(8):2363-73. doi: 10.1002/stem.2010. Epub 2015 Apr 21.
Stem cells provide a potentially unlimited source of cells for treating a plethora of human diseases. Regenerative therapies for retinal degenerative diseases are at the forefront of translation to the clinic, with stem cell-derived retinal pigment epithelium (RPE)-based treatments for age-related macular degeneration (AMD) already showing promise in human patients. Despite our expanding knowledge of stem cell biology, methods for deriving cells, including RPE have remained inefficient. Thus, there has been a push in recent years to develop more directed approaches to deriving cells for therapy. In this concise review, we summarize recent efforts that have been successful in improving RPE derivation efficiency by directing differentiation from human pluripotent stem cells using developmental cues important for normal RPE specification and maturation in vivo. In addition, potential obstacles for clinical translation are discussed. Finally, we review how derivation of RPE from human induced pluripotent stem cells (hiPSCs) provides in vitro models for studying mechanisms of retinal disease and discovering new avenues for treatment.
干细胞为治疗多种人类疾病提供了潜在的无限来源的细胞。视网膜退行性疾病的再生疗法处于向临床转化的最前沿,基于干细胞衍生的视网膜色素上皮(RPE)的治疗方法已经在老年黄斑变性(AMD)患者中显示出前景。尽管我们对干细胞生物学的了解不断扩大,但包括 RPE 在内的细胞获取方法仍然效率低下。因此,近年来人们一直在努力开发更有针对性的方法,以用于治疗的细胞。在这篇简明的综述中,我们总结了最近的一些努力,这些努力通过使用对体内正常 RPE 特化和成熟很重要的发育线索来指导分化,从而成功提高了从人多能干细胞中诱导 RPE 的效率。此外,还讨论了临床转化的潜在障碍。最后,我们综述了如何从人诱导多能干细胞(hiPSC)中诱导 RPE 为研究视网膜疾病的机制和发现新的治疗途径提供体外模型。